← All trials
NCT06022536
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 28, 2023
- Primary completion
- Oct 26, 2023
- Completion date
- Jul 12, 2024
- First posted
- Sep 5, 2023
- Last posted
- Sep 5, 2023
- Enrollment
- 69
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Qingdao UniversityLead sponsor
- Qingdao UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.